Kathmere Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Kathmere Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-30,000	Closed	-$66.3K	–	282
2023 Q2	$66.3K	Hold	30,000	–	–	0.01%	233
2023 Q1	$76.2K	Hold	30,000	–	–	0.01%	221
2022 Q4	$56.1K	Buy	+30,000	New	+$74.8K	0.01%	198

Kathmere Capital Management's PRTK Position: Q3 2023 in Review

Kathmere Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 30,000 shares — an estimated $66.3K sold.

Kathmere Capital Management first reported a position in PRTK in Q4 2022 and held it in 3 quarters. The position peaked at $76.2K in Q1 2023. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.

Kathmere Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Kathmere Capital Management sold 30,000 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $66.3K.
Kathmere Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2022 and held it in 3 quarters.
Kathmere Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $76.2K in Q1 2023.
0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.

Based on Kathmere Capital Management's 13F filing for Q3 2023, filed 11 Oct 2023.